Drug Type Antibody toxin conjugate |
Synonyms BL22 Immunotoxin, BL 22, BL-22 + [3] |
Target |
Mechanism CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hairy Cell Leukemia | Phase 2 | US | 01 Oct 2003 | |
Chronic Lymphocytic Leukemia | Phase 2 | - | - | |
Chronic Lymphocytic Leukemia | Phase 2 | - | - | |
Lymphoid Leukemia | Phase 2 | - | - | |
Non-Hodgkin Lymphoma | Phase 2 | - | - | |
Non-Hodgkin Lymphoma | Phase 2 | - | - | |
Acute Lymphoblastic Leukemia | Phase 1 | US | - | - |
Lymphoma | Preclinical | US | - | - |
Phase 2 | 36 | ekbrlxainp(woqlkyocoa) = abhfzjwdpi hulynnsrrz (orhmqzfhhy ) | - | 20 May 2008 | |||
Phase 2 | 35 | mwfcsickap(zlewnjfmjc) = kauuiokzsn xysjpevroo (jinomjluwf ) View more | Positive | 20 Jun 2007 | |||
Phase 1 | 18 | kgkahdbzmj(dpyfyrwhid) = rximlihtyd mlkvotgrzb (juyenuzokw ) | - | 20 Jun 2007 | |||
Phase 1 | 46 | jdzesymhhk(nprohhmdtx) = Neutralizing antibodies occurred in 11 (24%) of 46 patients (all HCL) mcxboqaxfu (znjpjaewyl ) View more | - | 20 Sep 2005 | |||
Not Applicable | 36 | oigyzqwoji(vrtmviiusm) = A total of 5 HCL patients had hemolytic uremic syndrome (HUS), 2 after cycle 2 of 30, 2 after cycle 3 of 40, and 1 after cycle 2 of 50 ug/Kg QOD x3 of BL22. HUS resolved in all HCL patients without dialysis after 6–10 days of plasmapheresis. maolbhexic (vjqbcpwrds ) | - | 15 Jul 2004 |